Karyopharm Therapeutics
357 articles about Karyopharm Therapeutics
-
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended September 30, 2022.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2022
11/1/2022
Karyopharm Therapeutics Inc. announced that the Company granted stock options to purchase an aggregate of 23,200 shares of Karyopharm's common stock and an aggregate of 16,000 restricted stock units to seven newly-hired employees.
-
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
10/31/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, a privately-held, leading international pharmaceutical company, announced that the European Commission has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis.
-
Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
10/20/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that on September 30, 2022, the Company granted a stock option to purchase 1,200 shares of Karyopharm's common stock and an award of 800 restricted stock units to one newly-hired employee.
-
Karyopharm to Participate at Upcoming September 2022 Investor Conferences
9/7/2022
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate in the following investor conferences in September:
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022
9/1/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 40,800 shares of Karyopharm's common stock and an aggregate of 28,000 restricted stock units to eight newly-hired employees.
-
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/4/2022
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2022.
-
Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference
8/2/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush Pacgrow Healthcare Conference.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 01, 2022
8/1/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 26,100 shares of Karyopharm's common stock and an aggregate of 18,000 restricted stock units to eight newly-hired employees.
-
Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022.
-
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
7/21/2022
Karyopharm Therapeutics Inc. and the Menarini Group today announced that the European Commission (EC) has granted Marketing Authorisation for NEXPOVIO.
-
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
7/20/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced new regulatory designations for eltanexor.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022
7/1/2022
Karyopharm Therapeutics Inc. announced that the Company approved the grant of stock options to purchase an aggregate of 32,600 shares of Karyopharm's common stock and an aggregate of 22,400 restricted stock units to 11 newly-hired employees.
-
Biogen has terminated its asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being evaluated as a treatment for ALS.
-
Karyopharm to Participate at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m. ET in New York, NY.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
Karyopharm Therapeutics Inc. announced that the Company approved the grant of stock options to purchase an aggregate of 136,700 shares of Karyopharm's common stock and an aggregate of 90,700 restricted stock units to 18 newly-hired employees.
-
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
5/26/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a Phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis and subgroup analyses and molecular classification data from the SIENDO study evaluating selinexor in endometrial cancer.
-
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
5/20/2022
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of NEXPOVIO® (selinexor).
-
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
5/12/2022
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis has been selected for a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress taking place June 9-12, 2022, in Vienna, Austria.